This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/pharmgkb/
n7http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/kegg-drug/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01121/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01121
rdf:type
n3:Drug
n3:description
Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
n3:generalReferences
# Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3508693 # Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3683877
n3:group
approved
n3:halfLife
22-25 hours.
n3:indication
Used to control certain seizures in the treatment of epilepsy.
owl:sameAs
n6:DB01121 n7:DB01121
dcterms:title
Phenacemide
adms:identifier
n12:PA164745309 n13:Phenacemide n14:4753 n15:46508400 n16:4589 n19:D00504 n20:DB01121 n21:C07428
n3:mechanismOfAction
Phenacemide binds to and blocks neuronal sodium channels or voltage sensitive calcium channels. This blocks or suppresses neuronal depolarization and hypersynchronization. Hypersynchronization is what often causes seizures.
n3:synonym
Phenurone
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 987 mg/kg; Oral, rabbit: LD<sub>50</sub> = 2500 mg/kg; Oral, rat: LD<sub>50</sub> = 1600 mg/kg
n3:foodInteraction
May be taken with food if stomach upset occurs.
n9:hasConcept
n10:M0046910
n3:IUPAC-Name
n4:271B4441-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4447-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4446-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4443-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4444-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4445-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4457-363D-11E5-9242-09173F13E4C5 n4:271B443F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B443D-363D-11E5-9242-09173F13E4C5 n4:271B4440-363D-11E5-9242-09173F13E4C5 n4:271B4459-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B443E-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:N03AX07
n3:H-Bond-Acceptor-Count
n4:271B444D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B444E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4448-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4449-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B444B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B444A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B444C-363D-11E5-9242-09173F13E4C5
n3:absorption
Almost completely absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
63-98-9
n3:Bioavailability
n4:271B4453-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4455-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4456-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4458-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4452-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4451-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4454-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4442-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B444F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4450-363D-11E5-9242-09173F13E4C5